Literature DB >> 17928194

Left ventricular to right atrial communication (Gerbode-type defect) after mitral valve replacement.

Ali Reza Moaref1, Amir Aslani, Mahmood Zamirian, Mohammed Bagher Sharifkazemi.   

Abstract

A 51-year-old woman with severe rheumatic mitral stenosis underwent mitral valve replacement. One week later, she was admitted with abdominal pain and lower extremities edema. On physical examination, her blood pressure was 120/60 mm Hg and holosystolic murmur (3/6) was heard at the left sternal border. Transesophageal echocardiography was done and revealed a shunt flow from the left ventricle to the right atrium in the 4-chamber and bicaval views. With careful examination of the interventricular septum, a small defect was seen in the membranous interventricular septum, which connects the left ventricle to the right atrium. The patient underwent surgical operation with diagnosis of iatrogenic left ventricular to right atrial communication (Gerbode-type defect). Intraoperative finding confirmed the preoperative diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17928194     DOI: 10.1016/j.echo.2007.08.035

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  4 in total

1.  Unusual presentation of Gerbode defect.

Authors:  Ajay Vallakati; Nishant Nerella; Ankur Lodha; Adnan Sadiq; Jacob Shani
Journal:  Tex Heart Inst J       Date:  2012

Review 2.  Gerbode defect: Another nail for the 3D transesophagel echo hammer?

Authors:  Tuncay Taskesen; Andrew Fred Prouse; Steven Lewis Goldberg; Edward Allen Gill
Journal:  Int J Cardiovasc Imaging       Date:  2015-02-14       Impact factor: 2.357

Review 3.  Acquired left ventricle-to-right atrium shunt: clinical implications and diagnostic dilemmas.

Authors:  Shi-Min Yuan
Journal:  Wien Klin Wochenschr       Date:  2015-03-17       Impact factor: 1.704

4.  Left ventricular to right atrial shunt (Gerbode defect): congenital versus acquired.

Authors:  Shi-Min Yuan
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-09-11       Impact factor: 1.426

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.